Strata Critical Medical Lifts 2026 EBITDA Outlook to $33M-$35M
SRTA sits 56% above its 52-week low of $3.675.
Summary
Strata Critical Medical raised its 2026 adjusted EBITDA guidance to $33M-$35M, up from $29M-$33M, signaling stronger profitability expectations. This follows a series of strategic acquisitions in June, including a heart and lung transplant recovery program, which likely contributed to the improved outlook. The raise comes just days after Reuters reported Q2 revenue was expected to decline 5.3% year-over-year, making this EBITDA lift a notable positive surprise. The company's Q1 results showed an 87% revenue surge, and the new guidance suggests margin expansion or cost discipline is taking hold. With a market cap near $480M, the $4M midpoint increase is material and could shift earnings models. Watch for the full Q2 release to confirm whether revenue headwinds are offset by operational gains.
At the time of this announcement, SRTA was trading at $5.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $480.2M. The 52-week trading range was $3.68 to $6.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.